Adult: Meclozine 25 mg and pyridoxine 50 mg tab
For the prophylaxis and treatment of nausea, vomiting and dizziness associated with motion sickness: 1-2 tabs once daily, given 1 hour before travelling. Doses may be repeated 24 hourly as needed. Child: Meclozine 25 mg and pyridoxine 50 mg tab
Dosage recommendations may vary among individual products and between countries (refer to specific product guidelines).
Oral Vertigo
Adult: Meclozine 25 mg and pyridoxine 50 mg tab
For the management of vertigo associated with diseases affecting the vestibular system: 1-4 tabs daily given in divided doses.
What are the brands available for Meclozine + Pyridoxine in Malaysia?
CYP2D6 is the dominant metabolising enzyme of meclozine. Based on the annotation of the US Food and Drug Administration (US FDA) drug label for meclozine, the genetic polymorphism of CYP2D6 gene which results in poor-, intermediate-, extensive-, and ultrarapid metaboliser phenotypes may contribute to the larger inter-individual variability in meclozine exposure. Therefore, it is recommended to monitor for adverse reactions and clinical effects accordingly in patients with CYP2D6 polymorphism.
Administration
Meclizine dihydrochloride + Pyridoxine hydrochloride tab: May be taken with or without food. May be taken w/ food to reduce GI discomfort.
Special Precautions
Patient with asthma, angle-closure glaucoma, myasthenia gravis, prostatic hyperplasia, bladder neck obstruction and pyloric or duodenal obstruction. Patients with CYP2D6 polymorphism. Renal and hepatic impairment. Children. Pregnancy and lactation.
Adverse Reactions
Significant: CNS depression; exacerbation of glaucoma. Blood and lymphatic system disorders: Rarely, agranulocytosis, leukaemia. Ear and labyrinth disorders: Vertigo. Eye disorders: Accommodation disturbance, blurred vision, diplopia. Gastrointestinal disorders: Xerostomia, constipation, gastric distress. Nervous system disorders: Drowsiness, insomnia, ataxia, headache. Psychiatric disorders: Agitation. Respiratory, thoracic and mediastinal disorders: Dry nose, dry throat.
Patient Counseling Information
This drug may cause drowsiness, if affected, do not drive or operate machinery.
Overdosage
Symptoms: Meclozine: CNS depression, drowsiness, coma, convulsions, hypotension, anticholinergic effects and CNS stimulation (e.g. hallucinations, seizures, trouble sleeping). Pyridoxine: Poor coordination, staggering, numbness, reduced sensation to touch, temperature and vibration. Management: Symptomatic and supportive treatment.
Drug Interactions
Meclozine: Additive antimuscarinic action with other antimuscarinic drugs (e.g. atropine, TCAs, MAOIs). May increase the risk of drowsiness with sedatives, antidepressants, pain relievers, anxiolytics, muscle relaxants and other antihistamines. Increased CNS depressant effect with barbiturates and tranquilisers.
Pyridoxine: May reduce the effect of levodopa (when concurrently used without a dopa-decarboxylase inhibitor) and altretamine. May decrease the serum concentrations of phenobarbital and phenytoin. Hydralazine, isoniazid, penicillamine and oral contraceptives may increase the requirements for pyridoxine.
Food Interaction
May increase the CNS depressant effect with alcohol.
Action
Description: Mechanism of Action: Meclozine, a piperazine derivative, is an antihistamine that inhibits vestibular end-organ receptors and prevents the activation of central cholinergic pathways.
Pyridoxine, a water-soluble vitamin, is involved in the metabolism of proteins, carbohydrates and fats. Additionally, it aids in the release of liver and muscle-stored glycogen and in the synthesis of γ-aminobutyric acid (GABA) within the central nervous system and haeme. Synonym(s): Meclozine: Meclizine.
Pyridoxine: Vitamin B6. Onset: Meclozine: Approx 1 hour. Duration: Meclozine: Approx 24 hours. Pharmacokinetics: Absorption: Meclozine: Time to peak plasma concentration: 3.1 ± 1.4 hours.
Pyridoxine: Readily absorbed from the gastrointestinal tract. Distribution: Meclozine: Volume of distribution: 7 L/kg. Metabolism: Meclozine: Metabolised in the liver into norchlorcyclizine.
Pyridoxine: Metabolised in the liver into the active forms pyridoxal phosphate and pyridoxamine phosphate. Excretion: Meclozine: Via urine and faeces as unchanged drug and metabolites. Elimination half-life: 5.2 ± 0.8 hours.
Pyridoxine: Via urine as metabolites. Elimination half-life: 15-20 days.
Chemical Structure
Meclozine Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 4034, Meclizine. https://pubchem.ncbi.nlm.nih.gov/compound/Meclizine. Accessed Apr. 25, 2024.
Pyridoxine Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 1054, Pyridoxine. https://pubchem.ncbi.nlm.nih.gov/compound/Pyridoxine. Accessed Apr. 29, 2025.
Storage
Store below 30°C. Protect from heat, moisture and direct sunlight.
Sign Out
